Utama › Karsinoma Sel Skuamosa Kepala dan Leher › California › Irvine
Kajian klinikal Karsinoma Sel Skuamosa Kepala dan Leher di Irvine, CA
11 kajian untuk Karsinoma Sel Skuamosa Kepala dan Leher sedang mencari peserta di lokasi dalam dan sekitar Irvine (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Mengambil pesertaFasa 1
- City of Hope at Irvine Lennar, Irvine
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Mengambil pesertaFasa 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Mengambil pesertaFasa 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Mengambil pesertaFasa 1/2
- City of Hope, Irvine, Irvine
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Mengambil pesertaFasa 2
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma
Mengambil pesertaFasa 1
- City of Hope at Irvine Lennar, Irvine
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
Mengambil pesertaFasa 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278432, Irvine
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Mengambil pesertaFasa 1
- Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Mengambil pesertaFasa 1
- City of Hope - Orange County Lennar Foundation Cancer Center /ID# 278589, Irvine
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
Mengambil pesertaFasa 1/2
- University of California, Irvine, Irvine
Kajian Karsinoma Sel Skuamosa Kepala dan Leher di bandar lain
- Houston, TX47 kajian
- Los Angeles, CA42 kajian
- Boston, MA40 kajian
- New York City, NY39 kajian
- Nashville, TN39 kajian
- St. Louis, MO28 kajian
- Arlington, VA26 kajian
- Philadelphia, PA26 kajian
- Chicago, IL26 kajian
- Atlanta, GA24 kajian
- San Antonio, TX22 kajian
- New Haven, CT22 kajian
Kajian lain di Irvine
- Kanser Paru-paru Bukan Sel Kecil25 kajian
- Kanser Payudara23 kajian
- Kanser (semua jenis)17 kajian
- Kanser Metastatik16 kajian
- Kanser Paru-paru15 kajian
- Mieloma Pelbagai14 kajian
- Kanser Prostat14 kajian
- Kanser Ovari12 kajian
- Kanser Pundi Kencing11 kajian
- Penyakit Alzheimer11 kajian
- Kanser Kolorektal10 kajian
- Kanser Pankreas10 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.